Figure 2
From: Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
ResA and ResB cells are cross-resistant against docetaxel. (a) Dose response curves showing the relative proliferation rate at increasing concentrations of the chemotherapeutic drugs paclitaxel and docetaxel in normal growth medium (containing 10 µM enzalutamide for ResA/ResB). All measurements are normalized to vehicle treated cells and set to 100. (b) Caspase 3/7 activity assay showing the percentage of apoptotic cells upon treatment with 10 nM paclitaxel/docetaxel for 48 hours in normal growth medium (containing 10 µM enzalutamide for ResA/ResB). (c) FPKM (fragments per kilobase million) mRNA expression of the apoptosis inhibitor MCL1 in conditions similar to their respective growth medium (+10 nM DHT for all cell-lines; +10 µM enz for ResA/ResB). (d) Dose response curves showing the proliferation at increasing concentrations of the PARP inhibitor olaparib and the pan-BCL-2 inhibitor obatoclax in normal growth medium (containing 10 µM enzalutamide for ResA/ResB). The shaded areas and error bars indicate the 95% confidence interval.
